These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 15210402)

  • 1. Dalteparin: pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic diseases.
    Pineo GF; Hull RD
    Eur J Med Res; 2004 Apr; 9(4):215-24. PubMed ID: 15210402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-molecular-weight heparins in clinical practice.
    Hunt D
    South Med J; 1998 Jan; 91(1):2-10. PubMed ID: 9438394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dalteparin: new indication. Prophylaxis in medical patients: no advance.
    Prescrire Int; 2005 Feb; 14(75):14-5. PubMed ID: 15751168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dalteparin: an update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic disease.
    Dunn CJ; Jarvis B
    Drugs; 2000 Jul; 60(1):203-37. PubMed ID: 10929935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
    Holzheimer RG
    Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low molecular weight heparins in the prevention of deep-vein thrombosis in general surgery.
    Breddin HK
    Semin Thromb Hemost; 1999; 25 Suppl 3():83-9. PubMed ID: 10549721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dalteparin sodium.
    Pineo GF; Hull RD
    Expert Opin Pharmacother; 2001 Aug; 2(8):1325-37. PubMed ID: 11585001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prevention of venous thromboembolism in internal medicine and neurology].
    Malý J; Dulícek P; Penka M; Malý R; Gumulec J
    Vnitr Lek; 2006 Mar; 52 Suppl 1():63-7. PubMed ID: 16637452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism.
    Lee AY; Rickles FR; Julian JA; Gent M; Baker RI; Bowden C; Kakkar AK; Prins M; Levine MN
    J Clin Oncol; 2005 Apr; 23(10):2123-9. PubMed ID: 15699480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dalteparin sodium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.
    Dunn CJ; Sorkin EM
    Drugs; 1996 Aug; 52(2):276-305. PubMed ID: 8841743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticoagulation with low-molecular-weight heparin in patients with heart diseases.
    Bechtold H; Janssen D
    Eur J Med Res; 2004 Apr; 9(4):186-98. PubMed ID: 15210399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy of unstable angina with the low molecular weight heparins.
    Ageno W; Turpie AG
    Vasc Med; 2000; 5(4):217-23. PubMed ID: 11213233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chrono-pharmacological study of once daily curative dose of a low molecular weight heparin (200 IU antiXa/kg of Dalteparin) in ten healthy volunteers.
    Mismetti P; Reynaud J; Tardy-Ponce B; Laporte-Simitsidis S; Scully M; Goodwyn C; Queneau P; Decousus H
    Thromb Haemost; 1995 Aug; 74(2):660-6. PubMed ID: 8585003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heparin and low-molecular-weight heparin.
    Gray E; Mulloy B; Barrowcliffe TW
    Thromb Haemost; 2008 May; 99(5):807-18. PubMed ID: 18449410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer-associated thrombosis: focus on extended therapy with dalteparin.
    Bick RL
    J Support Oncol; 2006 Mar; 4(3):115-20. PubMed ID: 16553136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are all low molecular weight heparins equivalent in the management of venous thromboembolism?
    Fareed J; Jeske W; Fareed D; Clark M; Wahi R; Adiguzel C; Hoppensteadt D
    Clin Appl Thromb Hemost; 2008 Oct; 14(4):385-92. PubMed ID: 18815137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
    Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
    Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Compliance with platelet count monitoring recommendations and management of possible heparin-induced thrombocytopenia in hospitalized patients receiving low-molecular-weight heparin.
    ten Berg MJ; van den Bemt PM; Huisman A; Schobben AF; Egberts TC; van Solinge WW
    Ann Pharmacother; 2009 Sep; 43(9):1405-12. PubMed ID: 19690229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of venous thromboembolism in pregnancy.
    Greer IA
    Eur J Med Res; 2004 Mar; 9(3):135-45. PubMed ID: 15096324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dalteparin for acute coronary syndromes.
    O'Loughlin DC
    Heart Dis; 1999; 1(5):329-36. PubMed ID: 11720639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.